Inserting Prevnar 13 Into Adult Treatment Guidelines Could Raise Questions For Practitioners
Uncertainty about the effect of Pfizer’s vaccine in patients that have already had Merck’s Pneumovax 23 could cause problems.
You may also be interested in...
Advisory committee votes 14-1 in favor of effectiveness and safety in adults 50 and older.
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
US FDA's advisors produce tie vote on bupivacaine extended-release solution for post-surgical analgesia; proponents valued its potential to to cut opioid use, while opponents questioned its efficacy.